Navigation Links
Sequenom Enters Into New $30.0 Million Credit Facility
Date:6/2/2011

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it and its subsidiary Sequenom Center for Molecular Medicine® (Sequenom CMM) have secured a $30.0 million financing commitment from Silicon Valley Bank’s San Diego-based team. Sequenom will use proceeds from the facility to support the development and commercialization of new products and other near term growth initiatives.

The credit facility consists of a term loan of up to $20.0 million, and a $10.0 million revolving line of credit to be used for the purchase of capital equipment to expand laboratory capacity and to fund working capital requirements, accounts receivable and inventory as Sequenom CMM prepares to commercialize and launch new laboratory developed tests.  

"The addition of this new credit facility enables us to extend the runway provided by financings put in place over the last year and to maintain a consistent level of liquidity as we move into an active growth phase for the company," said Paul V. Maier, CFO of Sequenom, Inc.  

The Sequenom CMM laboratory in San Diego, Calif. was recently awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP), while the laboratory based in Grand Rapids, Mich. received its third re-accreditation based on the results of recent onsite inspections.  In May of 2011, laboratory director Daniel H. Farkas, Ph.D., H.C.L.D. was advised of this national recognition and congratulated for the excellence of the services being provided, making the laboratory one of more than 7,000 CAP-accredited facilities worldwide.  

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company commi
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
2. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
3. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
4. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
5. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
6. Sequenom to Present at Two Financial Conferences in September
7. Sequenom to Present at Two Financial Conferences in March
8. Sequenom Appoints Two New Board Members
9. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
10. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
11. SEQUENOM Announces Launch of MassARRAY Compact 96 System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... CUMBERLAND, R.I. , Sept. 2, 2015 /PRNewswire/ ... has been enrolled in the multicenter Phase 2 ... for the long-term treatment of recurrent subfoveal choroidal ... AMD).  NT-503 is a unique vascular endothelial growth ... versatile ECT implant. "This landmark proof-of-concept ...
(Date:9/2/2015)... 2015 Aytu BioScience, Inc. (OTCQB: AYTU), a ... and related conditions, announced today that it has closed ... note financing, raising a total of $5.175 million, which ... Josh Disbrow , Chief Executive ... are intended to be used to conduct clinical studies ...
(Date:9/2/2015)... 2015 BioLight Life Sciences ... "Company"), a firm that invests in, manages and ... announced today that presentations highlighting its IOPtiMate™ system ... at the Ophthalmology Futures European Forum and the ... & Refractive Surgeons ("ESCRS"), both taking place in ...
(Date:9/2/2015)... September 2, 2015 Biovista ... Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. Hierbei ... Genomics Institute. Biovista unterstützt mit seiner ... die Behandlung anderer Krankheiten als denen, für die ... und sein Team bei der Wylder Nation ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... May 1 /PRNewswire-Asia/ -- Yongye Biotechnology International, Inc. (OTC ... distributor of plant and animal nutrient products located in ... of the independently owned Yongye branded retail stores in ... day sales.A Yongye branded retail store in Qianjiang City ...
... SAN DIEGO, May 1 BioMed Realty Trust, Inc. ... has entered into a new 15-year lease with Regeneron ... Landmark at Eastview campus in Tarrytown, New York, which ... lease expansion, Alan D. Gold, BioMed,s Chairman and Chief ...
... Held on May 15, 2009 at 8:00 am (Eastern) ... May 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: ... medical device R&D outsourcing company with operations in China ... release financial results for the first quarter of 2009 ...
Cached Biology Technology:Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 2Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 3BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals 2BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals 3WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release 2
(Date:8/17/2015)... Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... campaign for Q4 2015. The new marketing campaign is ... of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ... a leader in retail driven marketing and brand awareness ...
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Jr., M.D., one of the "fathers" of the ... receive the seventh annual American Association for Cancer ... Cancer Prevention Research. The award is given ... the field of cancer prevention research in basic, ...
... National Jewish Health have identified a simple gene-based blood ... patients, response to therapy than current tests. The test, ... care and help clear a backlog of promising medications ... published the results of a small "proof-of-principal" trial in ...
... Signal Patterns, SP Labs Election Patterns Report explains ... of voters; report also,reveals that openness and conscientiousness ... findings, PLEASANTVILLE, N.Y., Oct. 23 SP ... of scientific-based social web,applications that characterize and connect ...
Cached Biology News:Meyskens honored with AACR-Prevent Cancer Foundation award 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 3New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 2New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 3New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 4
...
... from 2 mM sodium phosphate buffer, pH ... D is a major lysosomal aspartyl protease ... kDa proenzyme. Overexpression of cathepsin D in ... risk of relapse and metastasis. Cathepsin D ...
... Grade Thrombin is a highly purified preparation ... with appropriate vectors. The preparation is functionally ... is free of detectable contaminating proteases. Prepared ... by certified tests to be negative for ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: